ConductScience.org, home

Paper32207804

Nonalcoholic Steatohepatitis: A Review.

Sheka AC and 5 others. JAMA, 2020. Cited by 1,195 papers, by iCite.

Cite this record

ConductScience Library. Nonalcoholic Steatohepatitis: A Review. Papers, record 32207804. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32207804

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Nonalcoholic Steatohepatitis: A Review.
PubMed
Journal
JAMA
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Review
PubMed
Citations, by iCite
1,195
iCite
Relative citation ratio, by iCite
61.6
iCite
Revised in PubMed
2020-03-31
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sheka ACAdam C
2Adeyi OOyedele
3Thompson JJulie
4Hameed BBilal
5Crawford PAPeter A
6Ikramuddin SSayeed

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
LiverMajor topic
Non-alcoholic Fatty Liver DiseaseMajor topic
Bariatric Surgery
Diagnosis, Differential
Disease Progression
Humans
Life Style
Liver Cirrhosis
Metabolic Syndrome
Obesity
Prevalence
United States

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R21 DK122832NIDDK NIH HHSUnited StatesR21DK122832PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Trials5

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT04626492Quantitative MRI Imaging in Diffuse Liver DiseasesBackgroundClinicalTrials.gov
NCT06097338Quantitative US for Evaluation of Hepatic Steatosis in MAFLD With UDFFBackgroundClinicalTrials.gov
NCT06334666The Efficacy of Pedometer-motivated Physical Activity for the Management of Patients With MASLD.ResultsClinicalTrials.gov
NCT06826807Hepatic Elastography-Enhanced Lifestyle Modification in MASLDBackgroundClinicalTrials.gov
NCT07513922The Correlation Between hs CRP TG Triglycerides Glucose Index in NAFLD and Liver FibrosisResultsClinicalTrials.gov

Download CSV of trials

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Erratum in32343314Typographical Error.https://conductscience.org/library/papers/32343314PubMed
Comment in32870291Nonalcoholic Steatohepatitis.https://conductscience.org/library/papers/32870291PubMed

Download CSV of comments and corrections

Cited by779

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,195 citations.

PMIDTitleJournalYearIn PapersSource
42989347TUDCA was identified as a potential therapeutic drug for nonalcoholic steatohepatitis complicated with hypercholesterolemia targeting ADRA2C by integrated bioinformatics and experimental verification.Biol Direct2026https://conductscience.org/library/papers/42989347PubMed
42985147Metabolic dysfunction-associated steatotic liver disease: Pathogenesis, complications and pharmacological treatment.EXCLI J2026https://conductscience.org/library/papers/42985147PubMed
42959101A multicohort proteomics-based machine learning score (MASHPredict) for noninvasive diagnosis and long-term prognostication of metabolic dysfunction-associated steatohepatitis.Front Immunol2026https://conductscience.org/library/papers/42959101PubMed
42958058Effects of bariatric surgery on non-invasive markers of MASLD: a retrospective analysis.BMC Gastroenterol2026https://conductscience.org/library/papers/42958058PubMed
42947668From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease.Front Pharmacol2026https://conductscience.org/library/papers/42947668PubMed
42927671Diet-induced obesity enhances the glycaemic response to glucagon in male C57BL/6J mice.Exp Physiol2026https://conductscience.org/library/papers/42927671PubMed
42882529
Targeting Gut Microbiota, Inflammation, and Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: Therapeutic Strategies and the Emerging Role of Time-Restricted Feeding.
Cells2026https://conductscience.org/library/papers/42882529PubMed
42846764Differential Associations of Dietary Inflammatory Index and Dietary Antioxidant Indices With Mortality Risk From MASLD/MetALD: Results From a Large Population-Based Study.Food Sci Nutr2026https://conductscience.org/library/papers/42846764PubMed
42763838Ovarian tumor domain-containing protein 1 deficiency attenuates metabolic dysfunction-associated steatotic liver disease by promoting the ubiquitination of HSP90α in hepatocytes.Mol Biomed2026https://conductscience.org/library/papers/42763838PubMed
42694403Shenling Baizhu powder alleviates non-alcoholic steatohepatitis by reducing PPARα-mediated NLRP3 inflammasome activation.Front Immunol2026https://conductscience.org/library/papers/42694403PubMed
42650052High Prevalence of Protective HSD17B13 Variant in Taiwan: An Analysis in Morbidly Obese Individuals and Liver Donors.Genes (Basel)2026https://conductscience.org/library/papers/42650052PubMed
42596894Associations between physical activity and dietary live microbe intake with non-alcoholic fatty liver disease: findings from the NHANES, 2007-2018.J Glob Health2026https://conductscience.org/library/papers/42596894PubMed
42572603Endogenous phosphatidylcholine 16:0/20:4 increases to promote liver regeneration in hepatectomy.iScience2026https://conductscience.org/library/papers/42572603PubMed
42566528TRIM29-dependent AKR1B10 degradation ameliorates MASH.Sci Adv2026https://conductscience.org/library/papers/42566528PubMed
42564158Natural polysaccharides as immunometabolic modulators in metabolic diseases: mechanisms and translational challenges.Front Immunol2026https://conductscience.org/library/papers/42564158PubMed
42558980Resmetirom Ameliorates Fibrogenesis in Hepatic Stellate Cells via Thyroid Hormone Receptor Alpha-Fatty-Acid Amide Hydrolase 1 Signaling Pathway.MedComm (2020)2026https://conductscience.org/library/papers/42558980PubMed
42518348Panax notoginseng saponins alleviates metabolic dysfunction-associated steatotic liver disease in mice by influencing Nrf2/MT2.Front Pharmacol2026https://conductscience.org/library/papers/42518348PubMed
42506440Mitochondrial Dysfunction in Metabolic-Syndrome-Related MASLD/MASH: Metabolic Mechanisms and Therapeutic Perspectives.Metabolites2026https://conductscience.org/library/papers/42506440PubMed
42483986Understanding the economic and healthcare burden of metabolic dysfunction-associated steatohepatitis: a real-world claims data analysis from Germany.J Comp Eff Res2026https://conductscience.org/library/papers/42483986PubMed
42471585A combi-elasto ultrasound based deep learning model on liver fibrosis staging for suspected MASLD/MASH patients.BMC Med Imaging2026https://conductscience.org/library/papers/42471585PubMed

See all 779 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32207804

GET https://conductscience.org/api/papers/v1/32207804/cited_by?page=2